Iso-ergoline derivatives for selective 5-HT1D agonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current migraine treatments face challenges such as excessive vasoconstriction due to strong agonism of the 5-HT1B receptor, undesirable agonism of dopamine receptors leading to nausea, and adverse effects from 5-HT2B receptor activation, necessitating a need for compounds that selectively agonize the 5-HT1D receptor with moderate 5-HT1B agonism and antagonize adrenergic and 5-HT2B receptors.
Innovation Solution
Development of iso-ergoline derivatives that include specific compounds and compositions capable of selectively agonizing the 5-HT1D receptor over the 5-HT1B receptor, while minimizing dopamine receptor agonism and antagonizing 5-HT2B and adrenergic receptors, thereby reducing adverse effects like vasoconstriction and nausea.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If strong agonism of 5-HT1B receptor is achieved for migraine treatment, then migraine symptoms are relieved, but excessive vasoconstriction and cardiovascular adverse effects occur
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of ergoline derivatives to alter receptor binding characteristics. Specifically, the compounds are designed to achieve selective agonism at 5-HT1D receptors with moderate agonism at 5-HT1B receptors, rather than strong agonism. This structural modification changes the pharmacological parameters to reduce vasoconstriction while maintaining migraine efficacy.
Solution Approach 2:
The patent applies local quality by creating compounds with differential receptor selectivity. The iso-ergoline derivatives are designed to have preferential binding affinity for 5-HT1D receptors over 5-HT1B receptors, achieving localized therapeutic action at the target receptor while minimizing off-target effects on vascular smooth muscle.
2Reliability
If agonism of dopamine receptors occurs in migraine compounds, then receptor binding is achieved, but nausea symptom is induced
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure to reduce dopamine receptor affinity. The iso-ergoline derivatives are designed with structural features that decrease binding to dopamine receptors while maintaining or enhancing 5-HT1D selectivity, thereby reducing the harmful dopaminergic side effect of nausea.
3Reliability
If agonism of 5-HT2B receptors occurs in migraine derivatives, then receptor binding is achieved, but cardiac and non-cardiac fibrosis is caused
Solution Approach 1:
The patent applies parameter changes by designing compounds with selective receptor profile. The iso-ergoline derivatives are structurally modified to achieve high selectivity for 5-HT1D receptors over 5-HT2B receptors, changing the binding parameters to minimize 5-HT2B agonism and associated fibrotic risks.
4Object-affected harmful factors
If high selectivity for 5-HT1D over 5-HT1B is achieved, then vasoconstriction is reduced, but migraine treatment efficacy may be compromised
Solution Approach 1:
The patent applies parameter changes by optimizing the balance between 5-HT1D and 5-HT1B agonism. The iso-ergoline derivatives are designed to maintain sufficient 5-HT1B agonist activity for migraine efficacy while achieving high 5-HT1D selectivity to reduce vasoconstriction, finding an optimal parameter balance.
Solution Approach 2:
The patent applies partial action by achieving moderate 5-HT1B agonism rather than strong agonism. This partial activation at 5-HT1B receptors is sufficient for migraine relief while avoiding the excessive vasoconstriction associated with strong agonism, when combined with potent 5-HT1D agonism.
Data Source
AI summary
Provided herein are novel iso-ergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1B receptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2B receptors using the compounds and compositions disclosed herein.